Home / Non‐Biological Complex Drugs / Polices & Legislation
Polices & Legislation
GDUFA regulatory priorities for 2016 include complex drugs
As part of the Generic Drug User Fee Amendments (GDUFA) of 2012, the US Food and Drug Administration (FDA) committed to prepare a yearly list of regulatory science priorities for generics based on input from industry and other stakeholders.
Is a new pathway for NBCDs on the way in the US?
The US Food and Drug Administration (FDA) does not formerly recognize non-biological complex drugs (NBCDs), with originators required to follow the new drug application (NDA) route and follow-on NBCDs using the generics – abbreviated new drug application (ANDA) – route [1].
FDA to set up abbreviated pathway for complex products
As part of the Generic Drug User Fee Amendments (GDUFA II) reauthorization recently agreed with industry [1], the US Food and Drug Administration (FDA) has committed to setting up a new approval pathway for drugs with complex active ingredients and formulations, as well as for drug-device combinations.
Generics News Research General
- Perspectives of prescribing practices in public...Generics/Research | Posted 15/01/2021
- A European pharmaceutical strategy promoting ge...Generics/General | Posted 08/01/2021
- Familiarity with substitution of prescription g...Generics/Research | Posted 11/12/2020
- Cost savings after switching to generic tacrolimusGenerics/Research | Posted 04/12/2020
Biosimilars News Research General
- Biosimilars of trastuzumabBiosimilars/General | Posted 19/09/2014
- Biosimilars of pegfilgrastimBiosimilars/General | Posted 31/10/2014
- Biosimilars in Australia – a-flagging and susta...Biosimilars/General | Posted 08/01/2021
- Biosimilars of rituximabBiosimilars/General | Posted 27/02/2015